item management s discussion and analysis of financial condition and results of operations 
summary in september  the company announced the planned divestitures of the zimmer and clairol businesses 
accordingly  their results have been reported as discontinued operations and excluded from consolidated sales and expenses for all years 
in february  the company announced its intention to separate the zimmer business in a tax free spin off to shareholders 
this transaction is expected to be completed by the end of the third quarter of in  bristol myers squibb reported billion in annual global sales  an increase of excluding foreign exchange over domestic sales  representing of worldwide sales  increased to billion  while international sales decreased a increase excluding foreign exchange to billion 
sales growth resulted from an increase due to volume  a increase from changes in selling prices and a decrease due to exchange rate fluctuations 
total company sales including discontinued operations increased excluding foreign exchange to billion 
the company s most important product lines made significant contributions to the company s sales growth  many of which experienced double digit growth on a worldwide basis 
three products  pravachol  taxol paclitaxel and glucophage  each exceeded billion in annual sales  while five additional products exceeded million in annual sales 
bristol myers squibb had product lines with more than million in annual sales  including with more than million in annual sales 
total company earnings continuing and discontinued operations before income taxes increased to billion from billion in net earnings increased to billion  basic and diluted earnings per share increased to and to  respectively 
earnings from continuing operations before income taxes  excluding restructuring charges and gain on sales of businesses  increased to billion in net earnings  on this basis  increased to billion  basic and diluted earnings per share increased to and to  respectively 
over the past five years  net earnings and diluted earnings per share from continuing operations  excluding gains from sales of businesses and restructuring and special charges  have increased at a compound annual growth rate of 
this growth rate enabled the company to achieve its goal of doubling earnings and earnings per share by the end of in  consistent with the company s mission to extend and enhance human life and to develop the highest quality products  the company invested more than billion in research and development  a increase over the prior year 
research and development expenditure dedicated to pharmaceutical products increased over with a compound annualized rate of over the past five years 
this significant investment has led to the discovery of innovative new products and the development of new indications for existing products leading  in  to eight regulatory approvals and the filing of three dossiers in the us notable approvals included glucovance  a new oral combination drug  and glucophage xr extended release tablets  a once daily version of glucophage  both for diabetes  vaniqa  a topical treatment for unwanted facial hair in women  and videx ec  a once a day  easier to digest  enteric coated form of videx for hiv aids 
also in  the company announced a number of research alliances  collaborations and commercialization agreements with other companies  including a global agreement excluding japan with novartis ag to codevelop and copromote tegaserod  novartis s new investigational drug treatment for irritable bowel syndrome  and a drug discovery alliance in the field of genomics with dimensional pharmaceuticals  inc  under which the company will receive worldwide rights to compounds discovered or developed through the collaboration 
this agreement is one of more than a dozen major genomics agreements the company has entered into over the past three years 
bristol myers squibb s financial position remains strong 
at december   the company held almost billion in cash  time deposits and marketable securities 
cash provided by operating activities reached billion  the highest in the past years 
returns to shareholders included dividend distributions of billion and stock repurchases of billion 
dividends per common share were 
in  increasing from 
per share paid in in december  the company announced a dividend increase  the th consecutive year that dividends have increased 
the indicated annual payment is per common share  a increase over as further evidence of its strong financial position  bristol myers squibb is one of only seven us industrial companies to receive a triple a credit rating from both moody s and standard poor s 
net sales sales increased in to billion  compared with increases of and in and  respectively 
the consolidated sales growth in resulted from an increase due to volume  a increase due to changes in selling prices and a decrease due to foreign exchange rate fluctuations 
in  the increase in sales reflected an increase due to volume  a increase due to changes in selling prices and a decrease due to foreign exchange rate fluctuations 
in  the increase in sales reflected an increase due to volume  a increase due to changes in selling prices and a decrease due to foreign exchange rate fluctuations 
domestic sales increased in and in  while international sales decreased in a increase excluding foreign exchange and increased in excluding foreign exchange 
in general  the business of the company is not seasonal 
in  worldwide pharmaceutical sales increased with us pharmaceutical sales up over the prior year 
key pharmaceutical product sales include sales of pravachol  a cholesterol lowering agent and the company s largest selling product  increased to  million primarily as a result of an increase in retail prescriptions 
domestic sales increased to  million  while international sales increased excluding foreign exchange to million 
glucophage sales increased to  million 
glucophage  the leading branded oral medication for treatment of non insulin dependent type diabetes  had a market share of in  up from in the prior year 
the marketing exclusivity for glucophage expired in september  however  no generic competition existed at the end of the year 
during the year  the company received fda approval for glucovance  an important advance in diabetes treatment  and for glucophage xr extended release tablets  a once daily version of glucophage 
sales of glucovance and glucophage xr since their launches were million and million  respectively 
sales of taxol  the company s leading anticancer agent  increased to  million as the product continued to benefit from increased use in ovarian  breast and non small cell lung cancer following standard chemotherapy 
generic paclitaxel became available in the us during the third quarter of sales of plavix  an anti platelet medication  increased to million 
results of the landmark cure trial clopidogrel in unstable angina to prevent recurrent ischemic events  jointly sponsored by the company and sanofi synthelabo  were announced in march in this international trial of more than  patients with acute coronary syndromes unstable angina or non q wave myocardial infarction  plavix was significantly superior to standard therapies  including aspirin  in reducing a cluster of clinical events heart attack  stroke and cardiovascular death 
sales of avapro  an angiotensin ii receptor blocker for the treatment of hypertension  increased to million 
avapro and plavix are cardiovascular products that were launched from the bristol myers squibb and sanofi synthelabo joint venture 
sales of buspar  the company s novel antianxiety agent  increased to million 
the us anxiolytic use patent expired in june the food and drug administration fda granted the company an additional six months exclusivity based on its performance of pediatric studies 
in november  the company received a patent covering the anxiolytic use of a buspar metabolite  a compound produced in the body by the oral administration of buspar and buspirone itself 
the patent was subsequently de listed during the course of litigation brought by generic manufacturers 
on march   three generic manufacturers received final approval from the fda for their respective abbreviated new drug applications andas for buspirone 
each of these three andas covers a separate dosage strength of buspirone 
fda approvals of additional andas for buspirone of any dosage strength can occur at any time beginning in september the litigation is on going 
sales of serzone  a novel antidepressant  increased to million 
sales of paraplatin  which is used in combination therapy for the treatment of ovarian cancer  increased to million 
sales of megace o s  indicated for the treatment of anorexia and cachexia in patients with aids  increased to million 
sales of maxipime  a fourth generation injectable cephalosporin antibiotic  increased to million 
sales of tequin  a quinolone antibiotic launched in december  were million 
in november  tequin became the first quinolone antibiotic to be prescribed for more than one million patients in the us after just months on the market 
sales of dovonex  an adult dermatological treatment  increased from the prior year to million 
sales of ifex  used in combination chemotherapy treatment  increased to million 
sales of captopril  an ace inhibitor sold primarily under the trademark capoten  declined to million due to generic competition 
sales from the oncology therapeutics network  a specialty distributor of anticancer medicines and related products  were  million for the year  an increase of over nonpharmaceutical sales included sales of bufferin  which increased excluding foreign exchange to million due to increased sales in japan  while sales of efferalgan  an effervescent analgesic sold primarily in france  increased excluding foreign exchange to million 
total infant formula sales decreased to  million 
sales of enfamil  the company s largest selling infant formula  remained at prior year levels of million worldwide 
sales of ostomy products decreased a increase excluding foreign exchange to million while sales of wound care products decreased a increase excluding foreign exchange to million 
earnings in  earnings from continuing operations before income taxes  excluding the nonrecurring items described below  increased to  million from  million in net earnings  on this basis  increased to  million compared with  million in basic earnings per share increased to from in the prior year and diluted earnings per share increased to from 
net earnings margins increased to in from in in  net earnings were  million  an increase over  excluding the nonrecurring items described below 
on this basis  basic earnings per share and diluted earnings per share both increased over and net earnings margins increased to in from in the company recorded certain nonrecurring items nonrecurring items in to earnings of continuing operations  including the gain on sales of businesses three pharmaceutical products estrace cream  ovcon and ovcon as well as its sea breeze brand in japan of million before taxes  million after taxes or 
per diluted share  as well as restructuring charges of million before taxes  million after taxes or 
per diluted share  in connection with workforce reductions and asset write downs related to the consolidation and closure of plants and facilities and other expenses 
in  the company recorded certain nonrecurring items to earnings of continuing operations  including the gain on sales of businesses ban  a s gea and hexachimie of million before taxes  million after taxes or 
per diluted share  as well as restructuring charges of million before taxes  million after taxes or 
per diluted share in connection with asset write downs and employee related costs related to the consolidation and closure of plants and facilities 
also  in  the company recorded a special charge of million before taxes  million after taxes  or 
per diluted share  to augment the reserve for breast implant liability and for prescription drug pricing litigation  offset by expected insurance recoveries 
the effective income tax rate on earnings from continuing operations before income taxes was in  compared with in  and in the effective income tax rate on earnings from continuing operations before income taxes  excluding the nonrecurring items  was in  compared with in  and in the effective income tax rate has decreased since due to increased income in lower tax jurisdictions 
total company earnings continuing and discontinued operations before taxes increased to  million from  million in net earnings increased to  million compared with  million in basic earnings per share increased to from in the prior year and diluted earnings per share increased to from 
in  net earnings were  million  an increase of from  million in  excluding the special charge 
on this basis  basic earnings per share were and diluted earnings per share were  both increasing over expenses total costs and expenses  excluding the nonrecurring items  as a percentage of sales  improved over the past three years to in compared with in  and in cost of products sold  as a percentage of sales  improved to in from in  principally due to manufacturing efficiencies 
in  cost of products sold as a percentage of sales increased to  compared with in  principally due to sales growth of lower margin products from the oncology therapeutics network 
advertising and promotion expenses increased over the prior year to  million in  primarily as a result of a direct to consumer campaign for pravachol and launch spending for glucovance and tequin 
in  advertising and promotion expenses increased from to  million 
as a percentage of sales  advertising and promotion expenses remained at prior year levels of and decreased from in  reflecting an improvement in the effectiveness of the advertising and promotion spending 
marketing  selling and administrative expenses  as a percentage of sales  decreased to in from in and in this decreasing trend is a result of slower rates of increase in marketing  sales force and general administrative expenses compared with revenue increases in the same period 
the company s investment in research and development totaled  million in  an increase of over  and to in  as a percentage of sales  compared with in and in this spending level reflects the company s commitment to research over a broad range of therapeutic areas and to clinical development of new products 
over the past five years  research and development expenses have increased at a compound annual growth rate of 
in  research and development spending dedicated to pharmaceutical products increased  and was of pharmaceutical sales compared with and in and  respectively 
as described in the notes to the financial statements  in the first quarter of  the company completed the sale of three pharmaceutical products estrace cream  ovcon and ovcon as well as its sea breeze brand in japan 
in  the company acquired cal c tose  a leading nutritional milk modifier product in mexico 
also  in  the company completed the sale of laboratori guieu  spa  an italian based gynecological  pediatric and dermatological products business 
in  the company acquired dong a biotech co  ltd  a marketer and distributor of pharmaceutical products in south korea 
also  in  the company divested its ban brand of anti perspirants and deodorants  a s gea  a denmark based generic drug business  and hexachimie  a specialty chemical manufacturer based in france 
discontinued operations clairol sales decreased to  million 
domestic sales decreased while international sales decreased excluding foreign exchange 
in  clairol sales increased to  million from  million in zimmer sales increased to  million  led by an increase in sales of knee joint replacements of to million  of hip replacements of to million and of fracture management products of to million 
in  zimmer sales increased to million from million in as described in the notes to the financial statements  in the third quarter of  the company completed the sale of matrix essentials  inc matrix  an affiliate of clairol 
matrix sales for the first six months of were million and were million for the full year in as described in note to the financial statements  in and the company recorded restructuring charges to discontinued operations of million and million before taxes  respectively  primarily in connection with workforce reductions 
in  the company recorded a pretax gain of million million after taxes on the sale of matrix 
the gain is included in the gain on disposal of discontinued operations 
as a result of the restructuring charges  net earnings from discontinued operations were million in and million in net earnings from discontinued operations  excluding the restructuring charges  increased to million in and decreased to million in geographic areas bristol myers squibb products are available in virtually every country in the world  the company s largest markets are the us  france  japan  germany and canada 
sales in the united states increased in products with strong growth in the region included glucophage  plavix  buspar  paraplatin and avapro 
in  sales in the united states increased  primarily due to growth of glucophage  taxol  enfamil  buspar  plavix  paraplatin and avapro 
sales in europe  mid east and africa decreased in sales increased  excluding foreign exchange  as a result of growth in france due to increased sales of pravachol and efferalgan  partially offset by decreased sales of capoten due to generic competition  in italy due to increased sales of taxol and avapro  and in spain due to increased sales of pravachol  avapro and plavix 
excluding foreign exchange  sales in germany were below prior year levels due to increased emphasis on generics and governmental spending controls 
in  sales in europe  mideast and africa increased excluding foreign exchange  due to sales growth of products including pravachol  taxol  plavix and avapro 
these increases were partially offset by decreases in sales of ostomy supplies and of capoten due to generic competition 
sales in other western hemisphere countries increased excluding foreign exchange in primarily as a result of growth in canada due to increased sales of plavix  avapro and enfamil  and in mexico due to growth of enfamil and cal c tose 
in  sales in other western hemisphere countries decreased a increase excluding foreign exchange primarily resulting from decreases in sales of capoten and pravachol  partially offset by growth in enfamil  avapro and plavix 
sales in the pacific region increased in excluding foreign exchange 
products with strong growth included bufferin  taxol and paraplatin in japan and nutritional products in the philippines and thailand 
in  pacific region sales increased excluding foreign exchange as a result of increases in bufferin  taxol and paraplatin 
the favorable effect from foreign exchange was experienced primarily in japan 
financial instruments cash and cash equivalents  time deposits and marketable securities totaled almost billion at december  compared with billion and billion at december  and  respectively 
working capital continued to improve with billion at december   compared with billion and billion at december  and  respectively 
cash and cash equivalents  time deposits and marketable securities  in addition to the conversion of other working capital items are expected to fund near term operations of the company 
the company is exposed to market risk due to changes in currency exchange rates 
to reduce this risk  the company enters into certain derivative financial instruments when available on a cost effective basis to hedge its underlying economic exposure 
these instruments also are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets 
derivative financial instruments are not used for trading purposes 
gains and losses on hedging transactions are offset by gains and losses on the underlying exposures being hedged 
foreign exchange option contracts and  to a lesser extent  forward contracts are used to hedge anticipated transactions 
the company s primary foreign currency exposures in relation to the us dollar are the euro  mexican peso  canadian dollar  brazilian real and japanese yen 
the table below summarizes the company s outstanding foreign exchange option contracts as of december  the fair value of option contracts  which changes over time  is estimated by using the black scholes model and is based on year end currency rates 
the fair value of option contracts should be viewed in relation to the fair value of the underlying hedged transactions and the overall reduction in exposure to adverse fluctuations in foreign currency exchange rates 
dollars in millions weighted average strike price notional amount carrying value fair value maturity option contracts purchased right to sell euro mexican peso brazilian real australian dollar philippine peso canadian dollar chinese renminbi british pound other currencies various right to buy japanese yen total at december   the company held right to sell option contracts with an aggregate notional amount  carrying value and fair value of  million  million and million  respectively 
these contracts related primarily to option contracts with the right to sell euros  mexican pesos and canadian dollars 
other contracts at december  included right to buy option contracts  primarily to buy japanese yen for us dollars 
these contracts had an aggregate notional amount and fair value of million and million  respectively  and no carrying value 
the company maintains cash and cash equivalents  time deposits and marketable securities with various financial institutions 
these financial institutions are located primarily in the us and europe 
company policy is designed to limit exposure to any one financial institution 
recently issued accounting standards in june  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 accounting for derivative instruments and hedging activities 
this statement requires that companies recognize all derivatives as either assets or liabilities on the balance sheet and measure these instruments at fair value 
in june  the fasb issued sfas no 
 accounting for derivative instruments and hedging activities deferral of the effective date of fasb statement no 
this statement deferred the effective date of sfas no 
to fiscal years beginning after june  in june  the fasb issued sfas no 
 accounting for certain derivative instruments and certain hedging activities  which made minor amendments to sfas no 
the company adopted sfas no 
 as amended  on january  the adoption of this accounting requirement will not have a material effect on either the company s consolidated financial statements or hedging programs 
euro conversion on january   certain members of the european union established fixed conversion rates between their existing currencies and the european union s common currency  known as the euro 
it is planned that by july  the participating countries will withdraw all currencies and use the euro exclusively 
the company has committed resources to conduct assessments and to take corrective actions to ensure it is prepared for the introduction of the euro 
the company is actively addressing the many areas involved with the introduction of the euro  including information management  finance  legal and tax 
this review includes the conversion of information technology  business and financial systems  evaluation of currency risk  and the effect on the company s financial instruments  as well as the impact on the pricing and distribution of company products 
the company believes the effect of introduction of the euro  as well as any related cost of conversion  will not have a material impact on the results of operations  financial condition and cash flows 
financial position cash and cash equivalents  time deposits and marketable securities at december  were denominated primarily in us dollar instruments with near term maturities 
the average interest yield on cash and cash equivalents was at december   while interest yields on time deposits and marketable securities averaged at december  short term borrowings and long term debt at december  are denominated primarily in us dollars but also include japanese yen long term debt of million 
during the year the company reduced short term borrowings by million primarily as a result of the paydown of the international commercial paper program 
internally generated cash provided by operations was billion in  billion in and billion in cash provided by operations continued to be the company s primary source of funds to finance operating needs and expenditures for new plants and equipment 
as part of the company s ongoing commitment to improve plant efficiency and maintain superior research facilities  the company has invested billion in capital expansion over the past three years 
cash flow from operations also included product liability payments  net of insurance recoverable receipts of million in  million in and million in cash provided by operations also was used over the past three years to pay dividends of billion  to finance billion of the company s share repurchase program and to fund business acquisitions  including the purchase of patents and trademarks  at a cost of million 
the company s share repurchase program authorizes the company to purchase common stock from time to time in the open market or through private transactions as market conditions permit 
during  the company purchased million shares of common stock at a cost of billion  bringing the total shares acquired since the program s inception to million 
in september  the company announced a billion increase in the stock repurchase program authorization 
during the past three years  the company has repurchased million shares at a cost of billion 
employment levels for continuing operations of  at december decreased from prior year levels of  sales per employee improved to thousand in from thousand in and thousand in return on stockholders equity  excluding nonrecurring items  improved over the last three years and was in  in and in forward looking information this form k annual report  and other written and oral statements that the company makes from time to time  contain certain forward looking statements within the meaning of the private securities litigation reform act of regarding  among other things  statements relating to goals  plans and projections with respect to the company s financial position  results of operations  market position  product development and business strategy 
these statements may be identified by the fact that they use words such as anticipate  estimate  expect  project  intend  plan  believe  and other words and terms of similar meaning in connection with any discussion of future operating or financial performance 
such forward looking statements are based on current expectations and involve inherent risks and uncertainties  including factors that could delay  divert or change any of them  and could cause actual outcomes and results to differ materially from current expectations 
these factors include  among other things  market factors  competitive product development  governmental regulations and legislation  patent positions and litigation 
further details and a discussion of these and other risks and uncertainties  are included in exhibit to this form k annual report 
we undertake no obligation to publicly update any forward looking statement  whether as a result of new information  future events or otherwise 

